Ivosidenib

• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 Phase III 4 countries Servier Affaires Medicales
• FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onur… Pending
  2025-521322-14-00 Phase II 1 country French Innovative Leukemia Organization
• A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia… Pending
  2025-523238-17-00 Phase II 1 country Fundacion PETHEMA
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 Phase III 14 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting
  2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting
  2022-501709-11-00 Phase III 11 countries Servier Affaires Medicales
• adIVO Recruiting
  2024-520219-42-00 Phase II/III 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leu… Recruiting
  2023-509055-14-00 Phase II 1 country Technische Universitat Dresden
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A… Recruiting
  2023-510155-37-00 Phase III 5 countries Institut De Recherches Internationales Servier IRIS
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste… Recruiting
  2023-508507-20-00 Phase III 7 countries Institut De Recherches Internationales Servier IRIS
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 Phase II 1 country Oslo University Hospital HF
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarc… Recruiting
  2024-514261-19-00 Phase I/II 3 countries Institut De Recherches Internationales Servier IRIS
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 Phase III 2 countries Unicancer
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended
  2022-501463-40-01 Phase III 10 countries Servier Affaires Medicales
• Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended
  2024-515352-20-00 Phase II 1 country Groupe Francophone Des Myelodysplasies
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended
  2022-502832-37-00 Phase III 12 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A Phase 3 study to test the AG-120 in combination with Azacitidine in comparison with the use of Azacitidine alone in patients ≥ 18 Years of… Ended
  2024-514309-73-00 Phase III 5 countries Institut De Recherches Internationales Servier IRIS
• A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in p… Ended
  2024-511722-31-00 Phase I/II 4 countries Celgene Corp.
• To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit… Halted
  2024-514051-15-00 Phase I (FiH) 1 country Medizinische Hochschule Hannover

Showing 1–20 of 20 trials